Nutritional basis of type 2 diabetes remission

Taylor, Roy; Ramachandran, Ambady; Yancy, William S.; Forouhi, Nita G.

doi:10.1136/bmj.n1449

Cited by 42 publications

(35 citation statements)

References 61 publications

(116 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reversal or remission of T2DM is now a key part of diabetes prevention programs [ 129 ]. Although progress has been made in the reversal of T2DM with low and very low calorie diets, there are some patients with T2DM who do not respond to these interventions and there is also uncertainty over compliance to dietary restriction and maintenance of T2DM reversal in a primary care setting [ 130 ]. Correction of insulin resistance is considered key to the prevention and reversal of T2DM [ 131 ] and tRES-HESP achieved this in the HATFF study without caloric or other dietary restriction [ 43 ].…”

Section: Concluding Remarks Future Perspective and Limitationsmentioning

confidence: 99%

Emerging Glycation-Based Therapeutics—Glyoxalase 1 Inducers and Glyoxalase 1 Inhibitors

Rabbani

Thornalley

2022

IJMS

View full text Add to dashboard Cite

The abnormal accumulation of methylglyoxal (MG) leading to increased glycation of protein and DNA has emerged as an important metabolic stress, dicarbonyl stress, linked to aging, and disease. Increased MG glycation produces inactivation and misfolding of proteins, cell dysfunction, activation of the unfolded protein response, and related low-grade inflammation. Glycation of DNA and the spliceosome contribute to an antiproliferative and apoptotic response of high, cytotoxic levels of MG. Glyoxalase 1 (Glo1) of the glyoxalase system has a major role in the metabolism of MG. Small molecule inducers of Glo1, Glo1 inducers, have been developed to alleviate dicarbonyl stress as a prospective treatment for the prevention and early-stage reversal of type 2 diabetes and prevention of vascular complications of diabetes. The first clinical trial with the Glo1 inducer, trans-resveratrol and hesperetin combination (tRES-HESP)—a randomized, double-blind, placebo-controlled crossover phase 2A study for correction of insulin resistance in overweight and obese subjects, was completed successfully. tRES-HESP corrected insulin resistance, improved dysglycemia, and low-grade inflammation. Cell permeable Glo1 inhibitor prodrugs have been developed to induce severe dicarbonyl stress as a prospective treatment for cancer—particularly for high Glo1 expressing-related multidrug-resistant tumors. The prototype Glo1 inhibitor is prodrug S-p-bromobenzylglutathione cyclopentyl diester (BBGD). It has antitumor activity in vitro and in tumor-bearing mice in vivo. In the National Cancer Institute human tumor cell line screen, BBGD was most active against the glioblastoma SNB-19 cell line. Recently, potent antitumor activity was found in glioblastoma multiforme tumor-bearing mice. High Glo1 expression is a negative survival factor in chemotherapy of breast cancer where adjunct therapy with a Glo1 inhibitor may improve treatment outcomes. BBGD has not yet been evaluated clinically. Glycation by MG now appears to be a pathogenic process that may be pharmacologically manipulated for therapeutic outcomes of potentially important clinical impact.

show abstract

Section: Concluding Remarks Future Perspective and Limitationsmentioning

confidence: 99%

Emerging Glycation-Based Therapeutics—Glyoxalase 1 Inducers and Glyoxalase 1 Inhibitors

Rabbani

Thornalley

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…There is recognition that no one intervention or diet will suit all, and there is acceptance that it is possible to achieve remission using a variety of dietary interventions (Taylor et al 2021). The evidence does suggest that it is essentially about amount of weight lost (ideally more than 10%) and if this weight loss can be maintained…”

Section: Other Type Of Interventions Have Also Shown Success a Popula...mentioning

confidence: 99%

Supporting patients to achieve remission of type 2 diabetes

James

2022

Nursing Standard

View full text Add to dashboard Cite

“…While these have been shown to be highly effective in controlled settings, they have not halted the inexorable increase in diabetes prevalence at the population level. The most likely cause for this failure is not because of the intervention design, but because the system driving obesity and subsequent diabetes is more complex than is represented in a controlled study or trial [6]. One way to characterise complex systems is through mapping of the feedbacks, delays, flows and accumulations (stocks) [7].…”

Section: Introductionmentioning

confidence: 99%

Exploring ways to respond to rising obesity and diabetes in the Caribbean using a system dynamics model

Guariguata

Garcia

Sobers

et al. 2022

PLOS Glob Public Health

View full text Add to dashboard Cite

Diabetes and obesity present a high and increasing burden of disease in the Caribbean that have failed to respond to prevention policies and interventions. These conditions are the result of a complex system of drivers and determinants that can make it difficult to predict the impact of interventions. In partnership with stakeholders, we developed a system dynamics simulation model to map the system driving diabetes and obesity prevalence in the Caribbean using Jamaica as a test case. The study aims to use the model to assess the magnitude changes necessary in physical activity and dietary intake to achieve global targets set by the WHO Global Action plan and to test scenarios for interventions to reduce the burden of diabetes and obesity. Continuing current trends in diet, physical activity, and demographics, the model predicts diabetes in Jamaican adults (20+ years) to rise from 12% in 2018 to 15.4% in 2030 and 20.9% by 2050. For obesity, it predicts prevalence to rise from 28.6% in 2018 to 32.1% by 2030 and 39.2% by 2050. The magnitude change necessary to achieve the global targets set by the World Health Organization is so great as to be unachievable. However, a combination of measures both upstream (including reducing the consumption of sugar sweetened beverages and ultra processed foods, increasing fruit and vegetable intake, and increasing moderate-to-vigorous activity) at the population level, and downstream (targeting people at high risk and with diabetes) can significantly reduce the future burden of diabetes and obesity in the region. No single intervention reduces the prevalence of these conditions as much as a combination of interventions. Thus, the findings of this model strongly support adopting a sustained and coordinated approach across various sectors to synergistically maximise the benefits of interventions.

show abstract

Nutritional basis of type 2 diabetes remission

Abstract: and colleagues explain how type 2 diabetes can be reversed by weight loss and avoidance of weight regain on 13 July 2021 by guest. Protected by copyright.

Cited by 42 publications

References 61 publications

Emerging Glycation-Based Therapeutics—Glyoxalase 1 Inducers and Glyoxalase 1 Inhibitors

Emerging Glycation-Based Therapeutics—Glyoxalase 1 Inducers and Glyoxalase 1 Inhibitors

Supporting patients to achieve remission of type 2 diabetes

Exploring ways to respond to rising obesity and diabetes in the Caribbean using a system dynamics model

Contact Info

Product

Resources

About